Pant, S., Schuler, M., Iyer, G., Witt, O., Doi, T., Qin, S., . . . Loriot, Y. (2023). Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): An international, single-arm, phase 2 study. The lancet. Oncology, 24(8), . https://doi.org/10.1016/S1470-2045(23)00275-9
Chicago-Zitierstil (17. Ausg.)Pant, Shubham, et al. "Erdafitinib in Patients with Advanced Solid Tumours with FGFR Alterations (RAGNAR): An International, Single-arm, Phase 2 Study." The Lancet. Oncology 24, no. 8 (2023). https://doi.org/10.1016/S1470-2045(23)00275-9.
MLA-Zitierstil (9. Ausg.)Pant, Shubham, et al. "Erdafitinib in Patients with Advanced Solid Tumours with FGFR Alterations (RAGNAR): An International, Single-arm, Phase 2 Study." The Lancet. Oncology, vol. 24, no. 8, 2023, https://doi.org/10.1016/S1470-2045(23)00275-9.